Patents by Inventor Mark Thomas Gladwin

Mark Thomas Gladwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230183321
    Abstract: Methods for the rapid elimination of carbon monoxide (CO) from CO-bound hemoglobin, myoglobin and cytochrome c oxidase in subjects with CO poisoning are described. The disclosed therapy involves the use of rationally designed, modified, regulator of CO metabolism (RcoM) proteins and pharmaceutical compositions thereof, which scavenge carbon monoxide from poisoned tissue. The recombinant RcoM compositions are infused into blood, where they rapidly sequester carbon monoxide and limit the toxic effects of carbon monoxide on cellular respiration, oxygen transport and oxygen utilization.
    Type: Application
    Filed: May 11, 2021
    Publication date: June 15, 2023
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Jason J. Rose, Anthony W. DeMartino, Jesus Tejero Bravo, Mark Thomas Gladwin, Matthew R. Dent
  • Publication number: 20220305051
    Abstract: Methods for the treatment of lung injury caused by chemical inhalation, smoke inhalation or microbial infection are described. The methods include administering a therapeutically effective amount of nitrite or a nitrite formulation. Nitrite formulations that include a nitrite salt and an anti-caking agent, such as sodium bicarbonate, and the use of such formulations, is also described.
    Type: Application
    Filed: September 4, 2020
    Publication date: September 29, 2022
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The UAB Research Foundation
    Inventors: Jason Joseph Rose, Mark Thomas Gladwin, Rakesh P. Patel, Sadis Matalon
  • Publication number: 20220088065
    Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. The method includes administering to a subject in need of treatment a therapeutically effective amount of inorganic nitrite. The nitrite may be administered by inhalation and may be nebulized. The nitrite may be administered at an emitted dose or in an escalated titrated dose. The nitrite may be a liquid formulation or a dry powder formulation.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 24, 2022
    Inventors: Mark Thomas Gladwin, Edwin Parsley, Hunter Clay Champion
  • Patent number: 11219640
    Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. The method includes administering to a subject in need of treatment a therapeutically effective amount of inorganic nitrite. The nitrite may be administered by inhalation and may be nebulized. The nitrite may be administered at an emitted dose or in an escalated titrated dose. The nitrite may be a liquid formulation or a dry powder formulation.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: January 11, 2022
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Aires Pharmaceuticals, Inc.
    Inventors: Mark Thomas Gladwin, Hunter Clay Champion, Edwin Parsley
  • Patent number: 10980864
    Abstract: It is disclosed herein that microperoxidases are capable of binding carbon monoxide (CO) with high affinity and displacing CO from hemoglobin, thereby acting as CO scavengers. The present disclosure provides methods of treating carboxyhemoglobinemia (or CO poisoning) in a subject by administering a therapeutically amount of an isolated or recombinant microperoxidase. Methods of removing CO from hemoglobin in blood or tissue by administering a therapeutically amount of an isolated or recombinant microperoxidase are also described. Methods of determining the effectiveness of a microperoxidase for removing CO from hemoglobin are further described.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: April 20, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Mark Thomas Gladwin, Jesus Tejero Bravo
  • Patent number: 10851153
    Abstract: Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: December 1, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Mark Thomas Gladwin, Jesus Tejero Bravo
  • Publication number: 20190389937
    Abstract: Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 26, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Mark Thomas Gladwin, Jesus Tejero Bravo
  • Publication number: 20180360873
    Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. Sodium nitrite is a naturally occurring compound that is commonly used as a preservative in meats. Due to its vasodilative properties and involvement in the nitric oxide pathway, drug development companies and researchers are also investigating sodium nitrite as a therapeutic agent.
    Type: Application
    Filed: April 16, 2018
    Publication date: December 20, 2018
    Inventors: Mark Thomas Gladwin, Hunter Clay Champion, Edwin Parsley
  • Publication number: 20170189495
    Abstract: It is disclosed herein that microperoxidases are capable of binding carbon monoxide (CO) with high affinity and displacing CO from hemoglobin, thereby acting as CO scavengers. The present disclosure provides methods of treating carboxyhemoglobinemia (or CO poisoning) in a subject by administering a therapeutically amount of an isolated or recombinant microperoxidase. Methods of removing CO from hemoglobin in blood or tissue by administering a therapeutically amount of an isolated or recombinant microperoxidase are also described. Methods of determining the effectiveness of a microperoxidase for removing CO from hemoglobin are further described.
    Type: Application
    Filed: May 19, 2015
    Publication date: July 6, 2017
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Mark Thomas Gladwin, Jesus Tejero Bravo
  • Publication number: 20160008394
    Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. Sodium nitrite is a naturally occurring compound that is commonly used as a preservative in meats. Due to its vasodilative properties and involvement in the nitric oxide pathway, drug development companies and researchers are also investigating sodium nitrite as a therapeutic agent.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 14, 2016
    Inventors: Mark Thomas Gladwin, Hunter Clay Champion, Edwin Parsley